Literature DB >> 33353946

The role of dissociation in ketamine's antidepressant effects.

Elizabeth D Ballard1, Carlos A Zarate2.   

Abstract

Ketamine produces immediate antidepressant effects and has inspired research into next-generation treatments. Ketamine also has short term dissociative effects, in which individuals report altered consciousness and perceptions of themselves and their environment. However, whether ketamine's dissociative side effects are necessary for its antidepressant effects remains unclear. This perspective examines the relationship between dissociative effects and acute and longer-lasting antidepressant response to ketamine and other N-methyl-D-aspartate (NMDA) receptor antagonists. Presently, the literature does not support the conclusion that dissociation is necessary for antidepressant response to ketamine. However, further work is needed to explore the relationship between dissociation and antidepressant response at the molecular, biomarker, and psychological levels.

Entities:  

Year:  2020        PMID: 33353946     DOI: 10.1038/s41467-020-20190-4

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  69 in total

1.  A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.

Authors:  Nancy Diazgranados; Lobna Ibrahim; Nancy E Brutsche; Andrew Newberg; Phillip Kronstein; Sami Khalife; William A Kammerer; Zenaide Quezado; David A Luckenbaugh; Giacomo Salvadore; Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Arch Gen Psychiatry       Date:  2010-08

2.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Authors:  Carlos A Zarate; Jaskaran B Singh; Paul J Carlson; Nancy E Brutsche; Rezvan Ameli; David A Luckenbaugh; Dennis S Charney; Husseini K Manji
Journal:  Arch Gen Psychiatry       Date:  2006-08

3.  Antidepressant effects of ketamine in depressed patients.

Authors:  R M Berman; A Cappiello; A Anand; D A Oren; G R Heninger; D S Charney; J H Krystal
Journal:  Biol Psychiatry       Date:  2000-02-15       Impact factor: 13.382

Review 4.  A New Paradigm for Achieving a Rapid Antidepressant Response.

Authors:  Gin S Malhi; Grace Morris; Erica Bell; Amber Hamilton
Journal:  Drugs       Date:  2020-06       Impact factor: 9.546

5.  Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.

Authors:  Carlos A Zarate; Nancy E Brutsche; Lobna Ibrahim; Jose Franco-Chaves; Nancy Diazgranados; Anibal Cravchik; Jessica Selter; Craig A Marquardt; Victoria Liberty; David A Luckenbaugh
Journal:  Biol Psychiatry       Date:  2012-01-31       Impact factor: 13.382

6.  Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).

Authors:  Maurizio Fava; Marlene P Freeman; Martina Flynn; Heidi Judge; Bettina B Hoeppner; Cristina Cusin; Dawn F Ionescu; Sanjay J Mathew; Lee C Chang; Dan V Iosifescu; James Murrough; Charles Debattista; Alan F Schatzberg; Madhukar H Trivedi; Manish K Jha; Gerard Sanacora; Samuel T Wilkinson; George I Papakostas
Journal:  Mol Psychiatry       Date:  2018-10-03       Impact factor: 15.992

7.  Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.

Authors:  Adriana Feder; Michael K Parides; James W Murrough; Andrew M Perez; Julia E Morgan; Shireen Saxena; Katherine Kirkwood; Marije Aan Het Rot; Kyle A B Lapidus; Le-Ben Wan; Dan Iosifescu; Dennis S Charney
Journal:  JAMA Psychiatry       Date:  2014-06       Impact factor: 21.596

8.  Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.

Authors:  James W Murrough; Dan V Iosifescu; Lee C Chang; Rayan K Al Jurdi; Charles E Green; Andrew M Perez; Syed Iqbal; Sarah Pillemer; Alexandra Foulkes; Asim Shah; Dennis S Charney; Sanjay J Mathew
Journal:  Am J Psychiatry       Date:  2013-10       Impact factor: 18.112

9.  Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.

Authors:  Carolyn I Rodriguez; Lawrence S Kegeles; Amanda Levinson; Tianshu Feng; Sue M Marcus; Donna Vermes; Pamela Flood; Helen B Simpson
Journal:  Neuropsychopharmacology       Date:  2013-06-19       Impact factor: 7.853

10.  Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.

Authors:  Allison C Nugent; Elizabeth D Ballard; Todd D Gould; Lawrence T Park; Ruin Moaddel; Nancy E Brutsche; Carlos A Zarate
Journal:  Mol Psychiatry       Date:  2018-02-27       Impact factor: 15.992

View more
  15 in total

1.  Commentary on the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder.

Authors:  Carlos A Zarate
Journal:  Can J Psychiatry       Date:  2021-03-19       Impact factor: 4.356

2.  Ketamine induces EEG oscillations that may aid anesthetic state but not dissociation monitoring.

Authors:  Shubham Chamadia; Jacob Gitlin; Jennifer Mekonnen; Breanna R Ethridge; Reine Ibala; Katia M Colon; Jason Qu; Oluwaseun Akeju
Journal:  Clin Neurophysiol       Date:  2021-10-08       Impact factor: 3.708

Review 3.  Psychedelics in the treatment of unipolar and bipolar depression.

Authors:  Oliver G Bosch; Simon Halm; Erich Seifritz
Journal:  Int J Bipolar Disord       Date:  2022-07-05

Review 4.  Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders.

Authors:  Chad R Johnson; Brian D Kangas; Emily M Jutkiewicz; Jack Bergman; Andrew Coop
Journal:  Biomedicines       Date:  2022-02-07

Review 5.  Ketamine treatment for depression: a review.

Authors:  Mani Yavi; Holim Lee; Ioline D Henter; Lawrence T Park; Carlos A Zarate
Journal:  Discov Ment Health       Date:  2022-04-15

Review 6.  Novel Insights Into the Neurobiology of the Antidepressant Response From Ketamine Research: A Mini Review.

Authors:  Michael Colla; Hanne Scheerer; Steffi Weidt; Erich Seifritz; Golo Kronenberg
Journal:  Front Behav Neurosci       Date:  2021-12-03       Impact factor: 3.558

7.  Toward Synergies of Ketamine and Psychotherapy.

Authors:  David S Mathai; Victoria Mora; Albert Garcia-Romeu
Journal:  Front Psychol       Date:  2022-03-25

8.  Case Report: Repeated Series of Ketamine Infusions in Patients With Treatment-Resistant Depression: Presentation of Five Cases.

Authors:  Maria Gałuszko-Wȩgielnik; Adam Włodarczyk; Wiesław Jerzy Cubała; Alina Wilkowska; Natalia Górska; Jakub Słupski
Journal:  Front Psychiatry       Date:  2021-12-02       Impact factor: 4.157

9.  Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats.

Authors:  Piotr Popik; Adam Hogendorf; Ryszard Bugno; Shaun Yon-Seng Khoo; Pawel Zajdel; Natalia Malikowska-Racia; Agnieszka Nikiforuk; Joanna Golebiowska
Journal:  Psychopharmacology (Berl)       Date:  2022-03-02       Impact factor: 4.415

Review 10.  Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor.

Authors:  Yan Wei; Lijia Chang; Kenji Hashimoto
Journal:  Mol Psychiatry       Date:  2021-05-07       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.